Evommune Starts Phase 2b Trial of EVO756 in Atopic Dermatitis

Evommune Starts Phase 2b Trial of EVO756 in Atopic Dermatitis

By, Admin 28 August 2025

Evommune, Inc. has dosed the first patient in its Phase 2b trial of EVO756, an oral small molecule designed to block MRGPRX2, a key driver of chronic inflammation. The study targets adults with moderate to severe atopic dermatitis (AD).

Why EVO756 Matters

  • Target: MRGPRX2, a receptor found on mast cells and sensory neurons.
  • Potential: First oral therapy addressing both inflammation and neurogenic itch.
  • Rationale: Translational data show increased mast cells and MRGPRX2 ligands in AD lesions.

Luis Peña, CEO of Evommune, said:

“MRGPRX2 is one of the most important new targets in chronic inflammation. EVO756 could be a critically needed oral therapeutic for AD and beyond.”

The Trial Design

  • Size: ~120 patients.
  • Type: Randomized, double-blind, placebo-controlled, dose-ranging.
  • Duration: 12 weeks.
  • Endpoints:
    - Primary: Change in Eczema Area and Severity Index (EASI) at Week 12.
    - Secondary: Pruritus-NRS to measure itch severity.

The trial compares EVO756 with placebo at multiple dose levels.

Expanding the Pipeline

Evommune is running two Phase 2 programs with EVO756 and EVO301 in AD, while also advancing a Phase 2b trial of EVO756 in chronic spontaneous urticaria. The company expects several clinical inflection points in 2026.

Dr. Eugene Bauer, CMO, highlighted the patient need:

“There is still a significant gap in treatment for AD itch. MRGPRX2 antagonism is exciting because it targets both mast cells and sensory neurons.”

Atopic Dermatitis: The Unmet Need

  • AD affects 15–20% of children and 1–3% of adults.
  • Symptoms include red lesions, dry scaly skin, and relentless itch.
  • The itch-scratch cycle worsens inflammation and disrupts sleep, leading to poor quality of life.

About MRGPRX2

  • A GPCR receptor on mast cells and sensory neurons.
  • Activated by ligands common during inflammation.
  • Plays a role in multiple chronic inflammatory diseases.
  • Potential applications: AD, chronic urticaria, asthma, migraine, IBD, interstitial cystitis, and pruritus.

About Evommune

Evommune is a clinical-stage biotech developing therapies that target the root drivers of chronic inflammation. Its goal: improve daily life for patients and prevent long-term consequences of uncontrolled inflammation.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!